Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, now LeonaBio, reports clinical-stage biopharmaceutical developments centered on novel therapeutics for diseases with high unmet medical needs. Recent company updates reflect the completed name change, the shift to the LONA ticker, and the acquired rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator for metastatic breast cancer.
The company’s historical Athira updates also cover small-molecule candidates designed to modulate the neurotrophic hepatocyte growth factor system, including ATH-1105 for neurodegenerative diseases such as ALS. Recurring announcements include clinical data presentations, operating and financial results, business updates, capital-structure actions such as the reverse stock split, and governance matters tied to stockholder approvals.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Athira Pharma, Inc. (NASDAQ: ATHA) revealed significant findings from its Phase 2 ACT-AD trial and new preclinical data during the AAN 2023 Annual Meeting. A post hoc analysis showed that patients treated with fosgonimeton exhibited a notable improvement in Mini-Mental State Examination (MMSE) scores (+1.6 pts, p=0.0350) and a decrease in neurodegeneration biomarkers. Additionally, preclinical data on ATH-1105 indicated prolonged survival and improved motor function in ALS mouse models. Athira continues to advance its exploration of the HGF/MET neurotrophic system as a potential treatment for neurodegenerative diseases, positioning ATHA for future clinical evaluation.
Athira Pharma, a biopharmaceutical company, announced upcoming presentations at the American Academy of Neurology (AAN) Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will feature new clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton for Alzheimer's disease, showcasing improvements in cognitive measures and plasma biomarkers. Additionally, preclinical research will support the therapeutic potential of fosgonimeton and ATH-1105 in neurodegenerative conditions, including ALS. The oral presentations will be led by Dr. Kevin Church and Dr. Hans J. Moebius on April 24 and 25, respectively. A poster presentation on ATH-1105's impact on motor function in an ALS model will occur on April 25. All presentations will be accessible on Athira's website post-event.
Athira Pharma (NASDAQ: ATHA) recently showcased preclinical data at the AD/PD 2023 conference, indicating that fosgonimeton may provide significant neuroprotective, neurotrophic, and anti-inflammatory benefits. Highlights include protection against neurite degeneration and cell death in neuronal cultures, reduced hyperphosphorylated tau levels, and decreased α-synuclein aggregation. The data suggests fosgonimeton could play a role in addressing Alzheimer’s and Parkinson’s diseases. Athira focuses on developing small molecules to restore neuronal health and progress its pipeline targeting the HGF/MET neurotrophic system.